Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes

被引:32
|
作者
Danne, Thomas
Rastam, Jacob
Odendahl, Rainer
Naeke, Andrea
Schimmel, Ulf
Szczepanski, Ruediger
Moeller, Johannes
Deiss, Dorothea
机构
[1] Kinderkrankenhaus auf Bult, D-30173 Hannover, Germany
[2] NovoNordisk AS, Bagsvaerd, Denmark
[3] Univ Schleswig Holstein Klinikum, Klin Kinder & Jugendmed, Lubeck, Germany
[4] Universitatskinderklin TU, Dresden, Germany
[5] Kinderklin Hagen, Hagen, Germany
[6] Kinderhosp, Osnabruck, Germany
[7] NovoNordisk GmbH, Mainz, Germany
[8] Charite, Klin Allgemeine Padiat, Berlin, Germany
关键词
basal/bolus; insulin aspart; pediatric; postprandial; quality of life;
D O I
10.1111/j.1399-5448.2007.00261.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Preprandial insulin injection in preschool children is complicated by irregular eating habits. Postprandial injection of rapid-acting insulin analogs such as insulin aspart (IAsp) offers the convenience of adjusting insulin dose to match food consumed. This trial compared safety and efficacy - including parental treatment satisfaction - of two basal-bolus regimens [IAsp plus Neutral Protein Hagedorn (NPH) insulin vs. regular human insulin (HI) plus NPH] in preschool children with type 1 diabetes. Methods: This study is a randomized, 12-wk, crossover trial comparing IAsp and regular HI in 26 children (17 boys and 9 girls; age: 2.4-6.9 yr). Regular HI was injected 30 min before and IAsp after or shortly before meals. Treatment satisfaction was assessed by a modified version of the WHO Diabetes Treatment Satisfaction Questionnaire (DTSQ-M). Results: Glycemic control for IAsp treatment was not different from that for regular HI treatment as assessed by mean postprandial blood glucose increment (IAsp vs. regular HI: 2.0 vs. 1.6 mmol/L), fructosamine (300 vs. 302 mu mol/L), and hemoglobin A(1c) (HbA(1c)) (7.7 vs. 7.6%). The relative risk of hypoglycemia was not significantly different [relative risk for IAsp/regular HI (95% CI): 1.06 (0.96-1.17), p = 0.225]. Mean total daily insulin dose (0.7 U/kg) remained constant throughout the trial with both treatments. The DTSQ-M score tended to be better for IAsp and reached statistical significance regarding the parental satisfaction with continuing IAsp treatment (p < 0.05). Conclusion: In preschool children, a basal-bolus treatment scheme with postprandial IAsp as bolus insulin was equally effective and safe compared with preprandial regular HI, although the parents showed a preference for the IAsp treatment.
引用
收藏
页码:278 / 285
页数:8
相关论文
共 50 条
  • [41] Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin
    De Leeuw, I
    Vague, P
    Selam, JL
    Skeie, S
    Lang, H
    Draeger, E
    Elte, JWF
    [J]. DIABETES OBESITY & METABOLISM, 2005, 7 (01): : 73 - 82
  • [42] Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes
    Nimri, Revital
    Lebenthal, Yael
    Shalitin, Shlomit
    Benzaquen, Hadasa
    Demol, Sharon
    Phillip, Moshe
    [J]. PEDIATRIC DIABETES, 2013, 14 (03) : 196 - 202
  • [43] Efficacy and safety of insulin glulisine (GLU) versus insulin lispro (LIS) as part of a basal-bolus insulin regimen in children and adolescents with Type 1 diabetes (T1DM)
    Philotheou, A.
    Arslanian, S.
    Blatniczky, L.
    Peterkova, V.
    Souhami, E.
    Danne, T.
    [J]. DIABETIC MEDICINE, 2008, 25
  • [44] Modelling study comparing complications in type 1 diabetes patients treated with either human or analogue insulin in a basal-bolus regimen
    Christensen, T. L.
    Valentine, W. J.
    Ray, J. A.
    Roze, S.
    Foos, V.
    Palmer, A. J.
    [J]. DIABETOLOGIA, 2006, 49 : 595 - 595
  • [45] Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial
    Rodbard, Helena W.
    Visco, Virginia E.
    Andersen, Henning
    Hiort, Line C.
    Shu, David H. W.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (01): : 30 - 37
  • [46] The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target&lt;7.0%
    Liebl, A.
    Prager, R.
    Kaiser, M.
    Binz, K.
    Gailwitz, B.
    [J]. DIABETOLOGIA, 2006, 49 : 610 - 611
  • [47] Glargine vs insulatard: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes - the Glargine and Aspart Study (GLASS)
    Davies, MJ
    Chatterjee, S
    Rengarajan, T
    Lawrence, IG
    McNally, PG
    [J]. DIABETOLOGIA, 2005, 48 : A329 - A329
  • [48] Beginning a Basal plus Mealtime Insulin Regimen Using Prandial Insulin Aspart in Insulin-Naive Adults With Type 2 Diabetes: Results from the A1chieve Study
    Haddad, Jihad
    Litwak, Leon E.
    Malek, Rachid
    Zilov, Alexey V.
    Chakkarwar, Praful N.
    Khamseh, Mohammad E.
    [J]. DIABETES, 2012, 61 : A302 - A302
  • [49] Switching from basal-bolus therapy with NPH insulin to basal-bolus therapy with the analog insulin detemir improves glycemic control and reduces hypoglycemic episodes, without weight gain, in type 1 and type 2 diabetes patients: Results from German subgroup of the PREDICTIVE study
    Ruhnau, Klaus-Juergen
    Hansen, Jes B.
    Dornhorst, Anne
    [J]. DIABETES, 2006, 55 : A133 - A133
  • [50] HYBRID CLOSED-LOOP WITH FASTER INSULIN ASPART COMPARED WITH STANDARD INSULIN ASPART IN VERY YOUNG CHILDREN WITH TYPE 1 DIABETES: A DOUBLE-BLIND, MULTICENTRE, RANDOMISED, CROSSOVER STUDY
    Ware, J.
    Allen, J.
    Boughton, C.
    Cezar, A.
    Hartnell, S.
    Wilinska, M.
    Thankamony, A.
    Deakin, M.
    Leyland, H.
    Phelan, K.
    Thornborough, K.
    Hovorka, R.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A56 - A56